Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC.

Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13.

2.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Gabriel R, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR.

Mol Ther. 2016 Mar;24(3):570-81. doi: 10.1038/mt.2015.197. Epub 2015 Oct 27.

3.

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD.

K√ľnkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC.

Cancer Immunol Res. 2015 Apr;3(4):368-79. doi: 10.1158/2326-6066.CIR-14-0200. Epub 2015 Jan 9.

4.

ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma.

Busch SE, Moser RD, Gurley KE, Kelly-Spratt KS, Liggitt HD, Kemp CJ.

Oncogene. 2014 May 15;33(20):2665-73. doi: 10.1038/onc.2013.208. Epub 2013 Jun 10.

5.

A targeted proteomics-based pipeline for verification of biomarkers in plasma.

Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, Wang P, Amon L, Chodosh LA, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG.

Nat Biotechnol. 2011 Jun 19;29(7):625-34. doi: 10.1038/nbt.1900.

6.

Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression.

Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ.

Cancer Res. 2011 Aug 1;71(15):5090-100. doi: 10.1158/0008-5472.CAN-11-0568. Epub 2011 Jun 8.

7.

Plasma proteome profiles associated with inflammation, angiogenesis, and cancer.

Kelly-Spratt KS, Pitteri SJ, Gurley KE, Liggitt D, Chin A, Kennedy J, Wong CH, Zhang Q, Buson TB, Wang H, Hanash SM, Kemp CJ.

PLoS One. 2011 May 12;6(5):e19721. doi: 10.1371/journal.pone.0019721.

8.

Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer.

Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, Holzman T, Coleman I, Feng LC, Lorentzen TD, Krasnoselsky AL, Wang P, Liu Y, Gurley KE, Amon LM, Schepmoes AA, Moore RJ, Camp DG 2nd, Chodosh LA, Smith RD, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG.

Proteomics Clin Appl. 2011 Apr;5(3-4):179-88. doi: 10.1002/prca.201000037. Epub 2011 Feb 15.

9.

Mapping tissue-specific expression of extracellular proteins using systematic glycoproteomic analysis of different mouse tissues.

Tian Y, Kelly-Spratt KS, Kemp CJ, Zhang H.

J Proteome Res. 2010 Nov 5;9(11):5837-47. doi: 10.1021/pr1006075. Epub 2010 Oct 14.

10.

Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer.

Kelly-Spratt KS, Philipp-Staheli J, Gurley KE, Hoon-Kim K, Knoblaugh S, Kemp CJ.

Oncogene. 2009 Oct 15;28(41):3652-62. doi: 10.1038/onc.2009.226. Epub 2009 Aug 3.

11.

Identification of glycoproteins from mouse skin tumors and plasma.

Tian Y, Kelly-Spratt KS, Kemp CJ, Zhang H.

Clin Proteomics. 2008 Dec 1;4(3-4):117-136.

12.

Differential Plasma Glycoproteome of p19 Skin Cancer Mouse Model Using the Corra Label-Free LC-MS Proteomics Platform.

Letarte S, Brusniak MY, Campbell D, Eddes J, Kemp CJ, Lau H, Mueller L, Schmidt A, Shannon P, Kelly-Spratt KS, Vitek O, Zhang H, Aebersold R, Watts JD.

Clin Proteomics. 2008 Dec 1;4(3-4):105.

13.

A mouse model repository for cancer biomarker discovery.

Kelly-Spratt KS, Kasarda AE, Igra M, Kemp CJ.

J Proteome Res. 2008 Aug;7(8):3613-8. doi: 10.1021/pr800210b. Epub 2008 Jul 15.

14.

Tumor suppression by p53 in the absence of Atm.

Bailey SL, Gurley KE, Hoon-Kim K, Kelly-Spratt KS, Kemp CJ.

Mol Cancer Res. 2008 Jul;6(7):1185-92. doi: 10.1158/1541-7786.MCR-07-2009. Epub 2008 Jun 26.

15.

Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells.

Pitteri SJ, Faca VM, Kelly-Spratt KS, Kasarda AE, Wang H, Zhang Q, Newcomb L, Krasnoselsky A, Paczesny S, Choi G, Fitzgibbon M, McIntosh MW, Kemp CJ, Hanash SM.

J Proteome Res. 2008 Apr;7(4):1481-9. doi: 10.1021/pr7007994. Epub 2008 Feb 27.

PMID:
18311905
16.

p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis.

Ruddell A, Kelly-Spratt KS, Furuya M, Parghi SS, Kemp CJ.

Oncogene. 2008 May 15;27(22):3145-55. Epub 2007 Dec 3.

PMID:
18059331
17.

Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.

Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, Piening BD, Feng LC, Kasarda E, Gurley KE, Eng JK, Chodosh LA, Kemp CJ, McIntosh MW, Paulovich AG.

J Proteome Res. 2007 Oct;6(10):3962-75. Epub 2007 Aug 21.

PMID:
17711321
18.

A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression.

Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM.

Genes Dev. 2006 Jan 1;20(1):47-64.

19.

High throughput quantitative analysis of serum proteins using glycopeptide capture and liquid chromatography mass spectrometry.

Zhang H, Yi EC, Li XJ, Mallick P, Kelly-Spratt KS, Masselon CD, Camp DG 2nd, Smith RD, Kemp CJ, Aebersold R.

Mol Cell Proteomics. 2005 Feb;4(2):144-55. Epub 2004 Dec 17.

20.

p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.

Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ.

PLoS Biol. 2004 Aug;2(8):E242. Epub 2004 Aug 17.

21.

BDNF activated TrkB/IRR receptor chimera promotes survival of sympathetic neurons through Ras and PI-3 kinase signaling.

Kelly-Spratt KS, Klesse LJ, Parada LF.

J Neurosci Res. 2002 Jul 15;69(2):151-9.

PMID:
12111796
22.
23.

Insulin receptor-related receptor expression in non-A intercalated cells in the kidney.

Bates CM, Merenmies JM, Kelly-Spratt KS, Parada LF.

Kidney Int. 1997 Sep;52(3):674-81.

Supplemental Content

Loading ...
Support Center